AR128079A1 - Composición farmacéutica que comprende un compuesto de quinazolina - Google Patents
Composición farmacéutica que comprende un compuesto de quinazolinaInfo
- Publication number
- AR128079A1 AR128079A1 ARP220103563A ARP220103563A AR128079A1 AR 128079 A1 AR128079 A1 AR 128079A1 AR P220103563 A ARP220103563 A AR P220103563A AR P220103563 A ARP220103563 A AR P220103563A AR 128079 A1 AR128079 A1 AR 128079A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- phenyl
- oxy
- hydroxy
- cyclopropyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- -1 QUINAZOLINE COMPOUND Chemical class 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 6
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 201000005202 lung cancer Diseases 0.000 abstract 2
- 208000020816 lung neoplasm Diseases 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000003566 oxetanyl group Chemical group 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
- 229920002554 vinyl polymer Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Una composición farmacéutica para tratar el cáncer colorrectal y/o cáncer de pulmón, la composición farmacéutica caracterizada porque comprende un compuesto de la siguiente fórmula (1) o una de sus sales y uno o más excipientes farmacéuticamente aceptables, donde R¹ es la siguiente fórmula (2) o (3), R¹ᵃ y R¹ᵇ, que son iguales o diferentes entre sí, son H o F, R² es halógeno, alquilo C₁₋₃, ciclopropilo, o vinilo, R³ es la siguiente fórmula (4), R⁴ es alquilo C₁₋₃, oxetanilo, tetrahidrofuranilo, tetrahidropiranilo, pirazolilo opcionalmente sustituido, piridilo opcionalmente sustituido, pirimidinilo opcionalmente sustituido, pirrolidinilo opcionalmente sustituido, o piperidinilo opcionalmente sustituido, R⁵ es etilo, isopropilo, ter-butilo, o cicloalquilo C₃₋₆, R⁶ᵃ y R⁶ᵇ, que son iguales o diferentes entre sí, son H o alquilo C₁₋₃ opcionalmente sustituido con un grupo seleccionado del grupo que consiste en F, OH, y N(CH₃)₂, o R⁶ᵃ y R⁶ᵇ forman ciclopropilo junto con el carbono al que están unidos, R⁷ es H, halógeno, o un grupo seleccionado del grupo que consiste en las siguientes fórmulas (6), (7), (8), y (9), R⁷ᵃ es H o alquilo C₁₋₃ opcionalmente sustituido con OH, X es O, Y es fenileno o piridindiílo, L es un enlace, alquileno C₁₋₃, o C=O, Z es NH o un grupo seleccionado del grupo que consiste en las siguientes fórmulas (10), (11), y (12), o, Y-L-Z es la siguiente fórmula (13). Reivindicación 13: Un método para tratar el cáncer colorrectal y/o cáncer de pulmón, caracterizado porque comprende administrar una cantidad efectiva de un compuesto de la fórmula (1) o una de sus sales a un sujeto, donde el compuesto de la fórmula (1) se selecciona del grupo que consiste en (4R)-1-[(2S)-2-(4-{4-[({6-ciclopropil-4-[(1S,4S)-2,5-diazabiciclo[2,2,1]heptan-2-il]-7-(6-fluoro-5-metil-1H-indazol-4-il)-2-[(oxan-4-il)oxi]quinazolin-8-il}oxi)metil]fenil}-1H-1,2,3-triazol-1-il)-3-metilbutanoil]-4-hidroxi-N-{(1R)-2-hidroxi-1-[4-(4-metil-1,3-tiazol-5-il)fenil]etilo}-L-prolinamida, (4R)-1-[(2S)-2-(4-{4-[({6-ciclopropil-4-[(1S,4S)-2,5-diazabiciclo[2,2,1]heptan-2-il]-7-(6-fluoro-5-metil-1H-indazol-4-il)-2-[(oxan-4-il)oxi]quinazolin-8-il}oxi)metil]fenil}-1H-1,2,3-triazol-1-il)-3-metilbutanoil]-4-hidroxi-N-[(1R)-2-hidroxi-1-{4-[4-(hidroximetil)-1,3-tiazol-5-il]fenil}etilo]-L-prolinamida, (4R)-1-[(2S)-2-(4-{4-[({6-ciclopropil-4-[(1S,4S)-2,5-diazabiciclo[2,2,1]heptan-2-il]-7-(6-fluoro-5-metil-1H-indazol-4-il)-2-[(oxan-4-il)oxi]quinazolin-8-il}oxi)metil]fenil}-1H-1,2,3-triazol-1-il)-3-metilbutanoil]-4-hidroxi-N-{(1R)-2-hidroxi-1-[4-(2-oxo-1,3-oxazolidin-3-il)fenil]etilo}-L-prolinamida, (4R)-1-[(2S)-2-(4-{4-[({6-ciclopropil-4-[(1S,4S)-2,5-diazabiciclo[2,2,1]heptan-2-il]-2-{[1-(2,2-difluoroetil)piperidin-4-il]oxi}-7-(6-fluoro-5-metil-1H-indazol-4-il)quinazolin-8-il}oxi)metil]fenil}-1H-1,2,3-triazol-1-il)-3-metilbutanoil]-4-hidroxi-N-{(1R)-2-hidroxi-1-[4-(4-metil-1,3-tiazol-5-il)fenil]etilo}-L-prolinamida, (4R)-1-[(2S)-2-(4-{4-[({6-ciclopropil-4-[(1S,4S)-2,5-diazabiciclo[2,2,1]heptan-2-il]-7-(6-fluoro-5-metil-1H-indazol-4-il)-2-[(oxan-4-il)oxi]quinazolin-8-il}oxi)metil]fenil}-1H-1,2,3-triazol-1-il)-3-metilbutanoil]-4-hidroxi-N-{(1R)-2-hidroxi-1-[4-(1-metil-1H-pirazol-5-il)fenil]etilo}-L-prolinamida, (4R)-1-[(2S)-2-(4-{4-[({6-ciclopropil-4-[(1S,4S)-2,5-diazabiciclo[2,2,1]heptan-2-il]-7-(6-fluoro-5-metil-1H-indazol-4-il)-2-[(oxan-4-il)oxi]quinazolin-8-il}oxi)metil]fenil}-1H-1,2,3-triazol-1-il)-3-metilbutanoil]-N-{(1R)-1-[4-(1-etilo-1H-pirazol-5-il)fenil]-2-hidroxietil}-4-hidroxi-L-prolinamida, (4R)-1-[(2S)-2-(4-{4-[({6-ciclopropil-4-[(1S,4S)-2,5-diazabiciclo[2,2,1]heptan-2-il]-7-(6-fluoro-5-metil-1H-indazol-4-il)-2-[(2S)-2-metoxipropoxi]quinazolin-8-il}oxi)metil]fenil}-1H-1,2,3-triazol-1-il)-3-metilbutanoil]-4-hidroxi-N-{(1R)-2-hidroxi-1-[4-(4-metil-1,3-tiazol-5-il)fenil]etilo}-L-prolinamida, y@@@(4R)-1-[(2S)-2-(4-{4-[({6-ciclopropil-4-[(1S,4S)-2,5-diazabiciclo[2,2,1]heptan-2-il]-7-(6-fluoro-5-metil-1H-indazol-4-il)-2-[(2S)-2-metoxipropoxi]quinazolin-8-il}oxi)metil]fenil}-1H-1,2,3-triazol-1-il)-3-metilbutanoil]-N-{(1R)-1-[4-(1-etilo-1H-pirazol-5-il)fenil]-2-hidroxietil}-4-hidroxi-L-prolinamida.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2021/049036 WO2023119677A1 (en) | 2021-12-24 | 2021-12-24 | Pharmaceutical composition comprising a quinazoline compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128079A1 true AR128079A1 (es) | 2024-03-20 |
Family
ID=86901812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220103563A AR128079A1 (es) | 2021-12-24 | 2022-12-23 | Composición farmacéutica que comprende un compuesto de quinazolina |
Country Status (8)
| Country | Link |
|---|---|
| CN (1) | CN118317774A (es) |
| AR (1) | AR128079A1 (es) |
| AU (1) | AU2022418089A1 (es) |
| CO (1) | CO2024008543A2 (es) |
| EC (1) | ECSP24039815A (es) |
| IL (1) | IL312972A (es) |
| TW (1) | TW202333714A (es) |
| WO (2) | WO2023119677A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023154766A1 (en) | 2022-02-09 | 2023-08-17 | Quanta Therapeutics, Inc. | Kras modulators and uses thereof |
| TW202412789A (zh) * | 2022-08-05 | 2024-04-01 | 日商安斯泰來製藥股份有限公司 | 用於誘導突變kras蛋白分解之雜環化合物 |
| WO2024034123A1 (ja) * | 2022-08-12 | 2024-02-15 | アステラス製薬株式会社 | 複素環化合物を含む医薬組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190186A1 (ar) * | 2017-02-02 | 2019-08-01 | Astellas Pharma Inc | مركب كينازولين |
| JP2021176820A (ja) * | 2018-07-31 | 2021-11-11 | アステラス製薬株式会社 | キナゾリン化合物を有効成分とする医薬組成物 |
| CR20230404A (es) * | 2021-02-15 | 2023-09-21 | Astellas Pharma Inc | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d |
-
2021
- 2021-12-24 WO PCT/JP2021/049036 patent/WO2023119677A1/en unknown
-
2022
- 2022-12-23 AU AU2022418089A patent/AU2022418089A1/en active Pending
- 2022-12-23 AR ARP220103563A patent/AR128079A1/es unknown
- 2022-12-23 IL IL312972A patent/IL312972A/en unknown
- 2022-12-23 WO PCT/JP2022/048717 patent/WO2023120742A1/en active Application Filing
- 2022-12-23 CN CN202280079125.0A patent/CN118317774A/zh active Pending
- 2022-12-23 TW TW111149632A patent/TW202333714A/zh unknown
-
2024
- 2024-05-23 EC ECSENADI202439815A patent/ECSP24039815A/es unknown
- 2024-06-28 CO CONC2024/0008543A patent/CO2024008543A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ECSP24039815A (es) | 2024-06-28 |
| CN118317774A (zh) | 2024-07-09 |
| IL312972A (en) | 2024-07-01 |
| TW202333714A (zh) | 2023-09-01 |
| WO2023119677A1 (en) | 2023-06-29 |
| AU2022418089A1 (en) | 2024-06-13 |
| WO2023120742A1 (en) | 2023-06-29 |
| CO2024008543A2 (es) | 2024-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR128079A1 (es) | Composición farmacéutica que comprende un compuesto de quinazolina | |
| PH12021550995A1 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| JP2018520105A5 (es) | ||
| PE20191755A1 (es) | Derivados de pirazol como inhibidores de malt 1 | |
| RU2419626C2 (ru) | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы | |
| IL295799A (en) | Trophomyosin receptor kinase (trk) degradation compounds and methods of use | |
| RU2020114660A (ru) | N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2 | |
| AR104963A1 (es) | Derivados de 2-(pirazolopiridin-3-il)pirimidina como inhibidores de jak | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| JP2018515555A5 (es) | ||
| RU2018127315A (ru) | Индуцирующие апоптоз средства для лечения злокачественной опухоли и иммунологических и аутоиммунных заболеваний | |
| RU2018115722A (ru) | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ | |
| PE20161022A1 (es) | Cocristales de (s)-n-metil-8-(1-((2'-metil-[4,5´-bipirimidin]-6-il)amino)propan-2-il)quinolina-4-carboxamida y sus derivados deuterados como inhibidores de proteinas quinasa dependientes de adn | |
| RU2011127232A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| RU2016129472A (ru) | Бициклические гетероциклические соединения и их применение в терапии | |
| JP2015533177A5 (es) | ||
| JP2015526519A5 (es) | ||
| JP2012528178A5 (es) | ||
| JP2016517878A5 (es) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| RU2011127402A (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| PE20120626A1 (es) | Composiciones farmaceuticas que comprende nilotinib | |
| JPWO2022173032A5 (es) | ||
| JP2013523814A5 (es) | ||
| RU2010134361A (ru) | Производные изоксазола в качестве модуляторов 11-бета-гидроксистероиддегидрогеназы 1 типа |